« Back
Sugammadex in Pediatric Congenital Myasthenia Syndrome
Sugammadex in Pediatric Congenital Myasthenia Syndrome
Submitted on 25 Jun 2018

Carie Ann Sirmon, MD, Shivani Mukkamala, MD
Emory University School of Medicine
This poster was presented at Georgia Society of Anesthesiologist Summer Meeting Student Posters Georgia Society of Anesthesiologist Summer Meeting Student Posters
Poster Views: 407
View poster »
Poster Abstract
Congenital myasthenic syndrome (CMS) is an inherited neuromuscular disorder caused by a defect in the acetylcholine receptor in the neuromuscular junction. While CMS differs from myasthenia gravis (MG) both in age of onset (pediatric vs. adult) and etiology (congenital vs. autoimmune), both are characterized by 1) reduced acetylcholine activity at the NMJ, and 2) muscle weakness that gets worse with exercise. Due to their baseline restrictive lung pathology and muscle weakness, myasthenic patients are predisposed to respiratory complications following anesthesia. The use of rocuronium is controversial in myasthenic patients. Sugammadex is routinely used in adults and case reports show safety and efficacy in adults with myasthenia gravis. While there is a lack of evidence as to its effectiveness in children, we believe sugammadex offers an attractive alternative to reversal of neuromuscular blockade without the use of anticholinesterases and antimuscarinics.

1. Benoît Plaud, Olli Meretoja, Rainer Hofmockel, Julien Raft, Peter A. Stoddart, Jacqueline H. M. van Kuijk, Yvonne Hermens, Rajinder K. Mirakhur; Reversal of Rocuronium-induced Meeting Abstracts with Sugammadex in Pediatric and Adult Surgical Patients. Anesthesiology 2009;110(2):284-294. doi: 10.1097/ALN.0b013e318194caaa.
2. Duke, James C., and Brian M. Keech, eds. Anesthesia Secrets. Fifth edition. Philadelphia, PA: Elsevier, Saunders, 2016.
3. Nag, Kusha et al. “Sugammadex: A Revolutionary Drug in Neuromuscular Pharmacology.” Anesthesia, Essays and Researches 7.3 (2013): 302–306. PMC. Web. 2 Mar. 2018
4. Sungur, Ulke, Z., Yavru, A., Camci, E., Ozkan, B., Toker, A. and Senturk, M. (2013), Rocuronium and sugammadex in patients with myasthenia gravis undergoing thymectomy. Acta Anaesthesiologica Scandinavica, 57: 745–748. doi: 10.1111/aas.12123
5. Palace, J., D. Lashley, J. Newsom-Davis, J. Cossins, S. Maxwell, R. Kennett, S. Jayawant, Y. Yamanashi, and D. Beeson. “Cli
Report abuse »
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters

A Novel Enzymatic Assay for Determination of Phosphatidylinositol in Biological Samples
Paul Templeton, Kyle C. Schmitt, Grigoriy Tchaga,and Gordon Yan

A Novel Method For Discovery of Peripheral Blood Biomarkers in Idiopathic Pulmonary Fibrosis Using Extensive Depletion and TMTcalibratorTM Tissue-Enhanced Plasma Proteomics
I. Pike1, M. Bremang1, P.J. Wolters 2, R. Gaster3, S. Turner3, M. Decaris3

Nikita Gandotra

Things just keep changing: Family caregivers' perceptions of the impact of Huntington's disease on caregiver burden
Jess Kaplonyi, Dr Christopher Lind, Catherine Christian, Irene Scott

The EurOPDX EDIReX project: towards a European Research Infrastructure on patient-derived cancer models
E. Vinolo 1, J.P. Morris 1, D.G. Alférez 2, J. Arribas 3,4,5, C. Bernadó 3,4,5, A. Bertotti 6, A. Bruna 7, A.T. Byrne 8, C. Caldas 7, R.B. Clarke 2, N. Conte 9, R. Corsi 10, S. Corso 6, M. Crespo 3, A. Dahmani 11, V. Dangles-Marie 11, D. Decaudin 11, Z. Dudová 12, A. Fiori 6, S. Giordano 6, M. Hauptsmann 13, M. Hidalgo 14, C. Isella 6, S. de Jong 15, J. Jonkers 13, A. Křenek 12, O. Krijgsman 13, D. Kouřil 12, J.C. Lacal 14, L. Lanfrancone 16, E. Leucci 17, G.M. Mælandsmo 18, E. Marangoni 11, J. Mason 9, M.Th. Mayrhofer 19, A. Mazzocca 6, T.S. Meehan 9, E. Montaudon 11, F. Nem